Barrigel® for Reducing Rectal Radiation in Prostate Cancer Recurrence

This clinical trial is designed to evaluate a product called Barrigel, which is made from a biodegradable material. The main goal is to determine if Barrigel can safely and effectively reduce the amount of radiation that reaches the rectum in men who are undergoing radiation therapy for prostate cancer that has returned after surgery. By creating more space between the rectum and the area where the prostate used to be, it is hoped that Barrigel can help protect the rectum from radiation damage, potentially leading to fewer side effects and better outcomes for patients. Participants in the study will receive injections of Barrigel to create a space between the rectum and the prostate bed before they begin their radiation treatment. The study involves multiple centers and is designed so neither the participants nor those assessing the outcomes know who receives the Barrigel injection. The study will look at whether this method effectively reduces radiation exposure to the rectum, while also monitoring for any safety concerns. The ultimate aim is to see if using Barrigel can provide a safer radiation therapy experience for patients with recurrent prostate cancer.